Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance

Heron Therapeutics IncTrade
iShares 0 3 Month Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while iShares 0 3 Month Treasury Bond ETF trades at $100.59. The key difference: iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXSGOV
Market Cap
$91.46M
Sector
HealthFixed Income
52-Week High
$1.96$100.74
52-Week Low
$0.39$100.28
Enterprise Value
$189.36M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

iShares 0 3 Month Treasury Bond ETF

SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.59, up slightly by 0.01% today. Technical indicators show a bullish trend with strong moving average support, though oscillators are neutral. The ETF provides exposure to short-term U.S. Treasury bills, offering liquidity and a low expense ratio of 0.09%. Recent news highlights institutional interest, such as Advisortrust Partners LLC acquiring a $615,000 position.

The outlook for SGOV is stable, benefiting from its role as a cash management tool amid rate uncertainty. Investment appeal lies in its safety and yield relative to cash, but risks include potential Fed rate hikes impacting short-term bond prices. Investors seeking low-risk income may find SGOV attractive, though returns are modest compared to equities.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.

Read more on SGOV